Drug intelligence / Profile preview

Anaerobutyricum soehngenii

Development stage: Unknown
Lead developer: Caelus Pharmaceuticals
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Duodenal (direct Infusion In Trials)

Overview

Anaerobutyricum soehngenii is a Gram-positive, non-spore-forming, obligately anaerobic, catalase-negative, butyrate-producing bacterium from the clostridial cluster XIVa of the phylum Firmicutes. Initially isolated from healthy infant feces as Eubacterium hallii strain L2-7, it was renamed in 2018. This next-generation probiotic is capable of converting D-/L-lactate and acetate into butyrate in acidic environments, conferring resilience through the gastrointestinal tract. Its mechanism includes modulating bile acid metabolism and increasing butyrate production, leading to beneficial effects on glucose metabolism and insulin sensitivity. It is being developed as a live biotherapeutic product for metabolic syndrome, prediabetes, and type 2 diabetes, with phase I/II and placebo-controlled trials in humans showing safety, improved glycemic control, and reduction in blood pressure. The bacterium’s action may involve increased GLP-1 production, beneficial bile acid modification, and reduced inflammation.

Other names: Eubacterium hallii strain L2-7

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on Anaerobutyricum soehngenii.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anaerobutyricum soehngenii.

Explore the full profile